uniQure N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
QURE Nasdaq 2836 www.uniqure.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for uniQure N.V.

uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap - Sep 30th, 2026 11:09 pm
uniQure Plunges on Additional Data From Huntington's Disease Study - Sep 30th, 2026 10:47 am
uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far - Sep 30th, 2026 9:48 am
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data - Sep 29th, 2026 4:08 pm
Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug - Sep 29th, 2026 2:56 pm
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit - Sep 29th, 2026 2:02 pm
Why Is uniQure Stock Sinking on Tuesday? - Sep 29th, 2026 8:28 am
UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 36% - Sep 29th, 2026 8:16 am
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - Sep 29th, 2026 7:31 am
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - Sep 29th, 2026 7:30 am
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - Sep 29th, 2026 6:58 am
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - Sep 29th, 2026 5:56 am
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression - Sep 29th, 2026 5:12 am
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch - Sep 27th, 2026 9:31 pm
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application? - Sep 8th, 2026 9:19 pm
ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment - Sep 4th, 2026 6:14 am
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Sep 3rd, 2026 12:16 pm
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Sep 3rd, 2026 9:30 am
QURE Submits Application for Gene Therapy for Huntington's Disease - Sep 3rd, 2026 8:30 am